#HVO hVIVO PLC – £16.8m RSV contract & Trading ahead of guidance December 13, 2023 – Posted in: Blog, hVIVO (HVO)
£16.8m full-service RSV contract with top five global pharma client Highlights · Pharma client is funding expedited manufacture of additional supply of RSV challenge agent · Confirmatory challenge cohort to verify infectivity of the new RSV challenge virus batch · Multiple cohort challenge trial to test efficacy of client’s RSV antiviral candidate · Trading ahead of previous market expectations driven by margin expansion hVIVO plc (AIM & Euronext: HVO), the world leader in testing…
Continue reading